SCHEDULE 13D/A: BML Investment Partners Significantly Reduces Stake in AN2 Therapeutics, Now Holds 1.4%

BML Investment Partners, L.P. has filed an amended Schedule 13D, revealing a substantial reduction in its beneficial ownership of AN2 Therapeutics, Inc. common stock to 1.4% after a series of sales in May and June 2025.

Summary

• BML Investment Partners, L.P., along with its general partner BML Capital Management, LLC and managing member Braden M. Leonard, filed an Amendment No. 2 to Schedule 13D concerning their holdings in AN2 Therapeutics, Inc.
• The reporting persons now beneficially own 427,432 shares of AN2 Therapeutics' Common Stock, which represents 1.4% of the class.
• This filing was triggered by an event on June 17, 2025, indicating a change in their ownership or investment intent.
• The shares were acquired for investment purposes using working capital.
• Between May 28, 2025, and June 17, 2025, BML Investment Partners, L.P. executed multiple sales, divesting a total of 5,322,000 shares of AN2 Therapeutics common stock at prices ranging from $1.01 to $1.16 per share.

Sentiment

Score: 3

Explanation: The significant reduction in stake by an investment firm, selling millions of shares, generally indicates a negative sentiment towards the issuer from the perspective of the reporting person, which could influence broader market perception negatively.

Negatives

• BML Investment Partners, L.P. significantly reduced its stake in AN2 Therapeutics, Inc., selling over 5.3 million shares in a short period.
• This substantial reduction in ownership by an investment firm could signal a lack of confidence or a shift in investment strategy regarding AN2 Therapeutics.

Risks

• The reporting persons explicitly reserve the right to dispose of their remaining securities at any time, which could lead to further selling pressure on AN2 Therapeutics' stock.
• The significant divestment by a large investor may negatively influence market sentiment and the company's share price.

Future Outlook

The Reporting Persons continuously evaluate AN2 Therapeutics, Inc., including its businesses, results of operations, and prospects. They reserve the right to acquire or dispose of additional securities at any time, or to formulate other purposes, plans, or proposals regarding the Issuer or its securities, based on their general investment and trading policies, market conditions, or other factors.

Industry Context

This filing primarily details the trading activity of a specific investment firm in AN2 Therapeutics, Inc. rather than providing broad industry context. However, significant divestment by an institutional investor in a biotechnology or pharmaceutical company like AN2 Therapeutics can be closely monitored by other market participants for potential implications on sector-specific sentiment or company-specific developments.

Stakeholder Impact

• Shareholders: Existing shareholders may experience negative sentiment and potential downward pressure on the stock price due to the significant selling by a large investor.
• Potential Investors: May view the divestment as a cautionary signal, potentially deterring new investment in AN2 Therapeutics.

Next Steps

• BML Investment Partners, L.P. may acquire additional securities of AN2 Therapeutics, Inc. in the future.
• BML Investment Partners, L.P. may dispose of its remaining securities of AN2 Therapeutics, Inc. at any time.
• BML Investment Partners, L.P. may formulate other purposes, plans, or proposals regarding the Issuer or its securities.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, BML Investment Partners, Schedule 13D, Common Stock, Beneficial Ownership, Stock Sales, Investment Filing, SEC Filing, Institutional Investor, Shareholder Activity